MedPath

A prospective study to evaluate the usefulness of thrombomodulin-alpha in patients with severe acute pancreatitis.

Phase 2
Recruiting
Conditions
Severe acute pancreatitis
Registration Number
JPRN-UMIN000029126
Lead Sponsor
rTM for SAP study group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with allergy for thrombomodulin alpha. Pregnant patients or patients who were suspected pregnancy. Patients whose informed consent could not be obtained. In case that doctors judged inappropriate for the entry.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival at the 28 day after onset of pancreatitis
Secondary Outcome Measures
NameTimeMethod
Prognostic score, occurrence of local complications, and performance status of the patients at the 28 day after onset of the pancreatitis
© Copyright 2025. All Rights Reserved by MedPath